newsfilter
← Latest News
ACCESS Newswire·

IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026

  • IGC Pharma completed enrollment in the CALMA Phase 2 trial evaluating IGC-AD1 for agitation in Alzheimer's dementia.
  • The trial randomized 168 participants, including planned over-enrollment to strengthen the evaluable dataset.
  • Final participant dosing is expected to conclude in early November 2026.
  • Topline results for the trial are expected in the fourth quarter of 2026 following database lock & unblinding.
  • The study was a multicenter, randomized, double-blind, placebo-controlled trial conducted across sites in the US & Canada.
  • The enrolled population had an average age of approximately 78 years, with 53% female participants.
  • Approximately 77% of participants were White, 16% were Black or African American, with the remainder identifying as other races or unlisted.
  • The primary endpoint is the change in agitation from baseline to week six measured by the Cohen-Mansfield Agitation Inventory.
  • The Data Safety Monitoring Committee has recommended continuing the trial without modification based on periodic safety reviews.
  • No treatment-related serious adverse events have been identified to date, though final safety analysis is pending database lock.
  • IGC Pharma is a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease & AI-enabled data tools.